- Home
- LPTX vs MIST Comparison
LPTX vs MIST Comparison
Compare LPTX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- MIST
- Stock Information
- Founded
- LPTX 2011
- MIST 2003
- Country
- LPTX United States
- MIST Canada
- Employees
- LPTX N/A
- MIST N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- MIST Health Care
- Exchange
- LPTX Nasdaq
- MIST Nasdaq
- Market Cap
- LPTX 119.6M
- MIST 100.3M
- IPO Year
- LPTX N/A
- MIST N/A
- Fundamental
- Price
- LPTX $2.55
- MIST $1.98
- Analyst Decision
- LPTX Strong Buy
- MIST Strong Buy
- Analyst Count
- LPTX 3
- MIST 3
- Target Price
- LPTX $7.50
- MIST $13.00
- AVG Volume (30 Days)
- LPTX 335.2K
- MIST 636.8K
- Earning Date
- LPTX 11-13-2024
- MIST 11-12-2024
- Dividend Yield
- LPTX N/A
- MIST N/A
- EPS Growth
- LPTX N/A
- MIST N/A
- EPS
- LPTX N/A
- MIST N/A
- Revenue
- LPTX N/A
- MIST N/A
- Revenue This Year
- LPTX N/A
- MIST N/A
- Revenue Next Year
- LPTX N/A
- MIST N/A
- P/E Ratio
- LPTX N/A
- MIST N/A
- Revenue Growth
- LPTX N/A
- MIST N/A
- 52 Week Low
- LPTX $1.68
- MIST $1.12
- 52 Week High
- LPTX $4.79
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- LPTX 37.35
- MIST 49.21
- Support Level
- LPTX $2.88
- MIST $1.92
- Resistance Level
- LPTX $3.27
- MIST $2.07
- Average True Range (ATR)
- LPTX 0.28
- MIST 0.20
- MACD
- LPTX -0.06
- MIST -0.03
- Stochastic Oscillator
- LPTX 12.71
- MIST 9.41
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).